[go: up one dir, main page]

UA29377C2 - Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів - Google Patents

Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів

Info

Publication number
UA29377C2
UA29377C2 UA5001725A UA5001725A UA29377C2 UA 29377 C2 UA29377 C2 UA 29377C2 UA 5001725 A UA5001725 A UA 5001725A UA 5001725 A UA5001725 A UA 5001725A UA 29377 C2 UA29377 C2 UA 29377C2
Authority
UA
Ukraine
Prior art keywords
csf
colony stimulating
protein
primates
activity
Prior art date
Application number
UA5001725A
Other languages
English (en)
Russian (ru)
Inventor
Стівен К. Кларк
Стивен К. Кларк
Рандал Дж. Кауфман
Гордон Г. Вонг
Елізабет А. Ванг
Элизабет А. Ванг
Original Assignee
Новартіс Аг
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартіс Аг, Новартис Аг filed Critical Новартіс Аг
Priority claimed from PCT/EP1985/000326 external-priority patent/WO1986000639A1/en
Publication of UA29377C2 publication Critical patent/UA29377C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід сстосується одержання білка, що володіє здатністю стимулювати ріст і диференціацію первинних кровотворних прогеніторних клітин, зокрема фактора стимулювання колоній. Винахід забезпечує спосіб одержання ФСК-білка шляхом технології рекомбінантної ДНК; вектори, що містять ген експресії зазначеного білка; мікроорганізми і клітинні лінії, трансформовані зазначеними векторами, і ФСК-білок, отриманий у такий спосіб.
UA5001725A 1984-09-19 1985-07-04 Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів UA29377C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65274284A 1984-09-19 1984-09-19
PCT/EP1985/000326 WO1986000639A1 (en) 1984-07-06 1985-07-04 Lymphokine production and purification

Publications (1)

Publication Number Publication Date
UA29377C2 true UA29377C2 (uk) 2000-11-15

Family

ID=46252828

Family Applications (1)

Application Number Title Priority Date Filing Date
UA5001725A UA29377C2 (uk) 1984-09-19 1985-07-04 Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів

Country Status (2)

Country Link
US (1) US5895646A (uk)
UA (1) UA29377C2 (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1309373A2 (en) * 2000-08-11 2003-05-14 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP2004529851A (ja) * 2000-09-12 2004-09-30 ジーントロール バイオセラピューティクス， インコーポレイテッド ヒトサイトカインの混合物を含む組成物およびその産生方法
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
DK2198876T3 (da) * 2003-10-24 2013-03-11 Nora Therapeutics Inc Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
AU2004289287A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
EP2391748A4 (en) * 2009-01-28 2012-08-01 Antigen Express Inc LI-KEY HYBRID PEPTIDES MODULATING IMMUNE RESPONSE TO FLU
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230697A (en) * 1978-07-03 1980-10-28 Morinaga Milk Industry Co. Ltd. Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same
IN150740B (uk) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4658018A (en) * 1984-03-13 1987-04-14 Immunex Corporation Process for producing homogeneous colony stimulating factor
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
IL77080A (en) * 1984-11-20 1998-02-08 Schering Biotech Corp Polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity, vectors and transformed cells for their production and pharmaceutical compositions comprising them
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions

Also Published As

Publication number Publication date
US5895646A (en) 1999-04-20

Similar Documents

Publication Publication Date Title
UA29377C2 (uk) Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
EP0215126A4 (en) STIMULATION FACTOR OF HUMAN GRANULOCYTE COLONIES.
NZ212645A (en) Method for producing primate granulocyte-macrophage colony stimulating factor (gm-csf)
ES8606489A1 (es) Un metodo de producir una proteina de interleuquina-2-humana no glicosilada sustancialmente pura
DE3479321D1 (en) Biosynthetically produced human nerve growth factor, process for producing it, compositions containing it, dna sequence encoding it, vectors containing the sequence and host cells transformed thereby
GEP19970775B (en) Method for the production of human erythropoietin
AU2443488A (en) Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
NZ211827A (en) Production of polypeptides having interferon activity, polypeptide compositions and dna
HUT58798A (en) Process for producing growth factor of parenchimic hepatic celles, the gen for coding this and transformants for producing this factor
DE3689899D1 (de) Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
NZ216834A (en) Production of bovine growth hormone by use of recombinant dna
AU2209988A (en) Method for increasing the expression of polypeptides in recombinant cell culture
DE3925550C2 (uk)
EP0171000A3 (en) Process for producing heterologous matured protein or peptide
Hoang et al. Macromolecules stimulating human granulocytic colony-forming cells, precursors of these cells, and primitive erythroid progenitors: some apparent nonidentities
JPS6427493A (en) Production of protein containing nonnatural-type amino acid
KR100254829B1 (ko) 재조합 인간 과립구 대식세포 콜로니자극인자의 개선된 정제 방법
GB8625180D0 (en) Expression of genes in yeast
EP0287248A2 (en) A human cell line capable of producing human interleukin 3 having mast cell growth activity
EP0165759A3 (en) Mammalian promotors useful in yeast expression
JPS6485095A (en) Novel physiologically active polypeptide
JPS6485094A (en) Novel physiologically active polypeptide
ES2002164A6 (es) Un metodo para producir un polipeptido o una gicoproteina que tiene una actividad de factor estimulante de colonias de granulocitos humanos.
KR970074932A (ko) 효모를 이용한 사람의 인터루킨-6의 제조 방법
KR980009464A (ko) 재조합 효모로부터 인간 알파 인터페론의 대량 생산방법